Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...

EST: Adds comments from Seeking Alpha analyst BioCGT Investor Eli Lilly (NYSE:LLY) on Thursday reported its Q4 2024 results, exceeding Wall Street forecasts and indicating a more than twofold rise in ...

B, consensus $58.91B. The company said, “The company anticipates 2025 revenue to be between $58.0 billion and $61.0 ...

The company disclosed preliminary results in mid January, but it left out important metrics such as earnings per share for the fourth quarter.

Eli Lilly (NYSE: LLY) has become a beast in healthcare. The excitement surrounding its GLP-1 drugs, Mounjaro and Zepbound, has helped boost its market capitalization to around $650 billion.

PNT-2001 is under clinical development by Eli Lilly and Co and currently in Phase ... Africa and Asia-Pacific. Lilly is headquartered in Indianapolis, Indiana, the US. For a complete picture of ...

Shares of Eli Lilly & Co. were headed for their worst day in nearly four years on Tuesday after the drugmaker provided a fourth-quarter revenue outlook that was below expectations, citing slower ...

Shelby Knowles / Bloomberg via Getty Images Eli Lilly's Zepbound can be covered by Medicare Part D plans after the FDA approved the drug as a treatment for sleep apnea last month. Weight loss ...

Expect to see the pace accelerate at the Eli Lilly ... with the Indiana Economic Development Corp. to buy 1,400 acres on the southern side of LEAP on the northside of Ind. 32 on Lebanon’s ...

Expect to see the pace accelerate at the Eli Lilly and Co. project on Lebanon’s north side as weather warms. The $9 million pharmaceutical complex is about 7% complete, Jeff Wagner, community ...